$1.25
0.40%
Nasdaq, Sep 24, 04:00 pm EDT. Closed.
ISIN
US83558L1052
Symbol
SNOA

Sonoma Pharmaceuticals, Inc. Target price 2026 - Analyst rating & recommendation

Sonoma Pharmaceuticals, Inc. Classifications & Recommendation

Buy
86%
Hold
14%

Sonoma Pharmaceuticals, Inc. Price Target

Target Price $15.10
Price $1.25
Potential
Number of Estimates 3
3 Analysts have issued a price target Sonoma Pharmaceuticals, Inc. 2027 . The average Sonoma Pharmaceuticals, Inc. target price is $15.10. This is higher than the current stock price. The highest price target is
$15.54 1,148.19%
register free of charge
, the lowest is
$14.95 1,100.64%
register free of charge
.
A rating was issued by 7 analysts: 6 Analysts recommend Sonoma Pharmaceuticals, Inc. to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Sonoma Pharmaceuticals, Inc. stock has an average upside potential 2027 of . Most analysts recommend the Sonoma Pharmaceuticals, Inc. stock at Purchase.

Sales and Margin forecast 2027, 2028 & 2029

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Mar '26 2027
Estimates
Revenue Million $ 19.53 21.90
36.67% 12.11%
Net Margin -16.28% -10.11%
32.75% 37.91%

3 Analysts have issued a sales forecast Sonoma Pharmaceuticals, Inc. 2027 . The average Sonoma Pharmaceuticals, Inc. sales estimate is

$21.9m
unlock
. This is
0.11% lower
unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$22.5m 2.82%
unlock
, the lowest is
$21.0m 4.03%
unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2026 $19.5m 36.67%
2027
$21.9m 12.11%
unlock
2028
$27.5m 25.57%
unlock

3 Sonoma Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2027. The average Sonoma Pharmaceuticals, Inc. net profit estimate is

$-2.2m
unlock
. This is
2.21% higher
unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-2.1m 5.75%
unlock
, the lowest is
$-2.3m 0.88%
unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2026 $-3.2m 8.09%
2027
$-2.2m 30.50%
unlock
2028
$340k 115.38%
unlock

Net Margin

2026 -16.28% 32.75%
2027
-10.11% 37.91%
unlock
2028
1.24% 112.27%
unlock

Earnings per share, P/E ratio and EV/sales Estimates 2027, 2028 & 2029

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Mar '26 2027
Estimates
Earnings Per Share $ -1.89 -0.46
32.26% 75.66%
P/E negative
EV/Sales 0.03

3 Analysts have issued a Sonoma Pharmaceuticals, Inc. forecast for earnings per share. The average Sonoma Pharmaceuticals, Inc. EPS is

$-0.46
unlock
. This is
20.69% higher
unlock
than earnings per share in the financial year 2026. The highest EPS forecast is
$-0.48 17.24%
unlock
, the lowest is
$-0.44 24.14%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2026 $-1.89 32.26%
2027
$-0.46 75.66%
unlock
2028
$0.07 115.22%
unlock

P/E ratio

Current -2.15 10.92%
2027
-2.69 25.31%
unlock
2028
17.44 748.33%
unlock

Based on analysts' sales estimates for 2027, the Sonoma Pharmaceuticals, Inc. stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 0.03 86.96%
2027
0.03 15.67%
unlock
2028
0.03 20.46%
unlock

P/S ratio

Current 0.27 40.96%
2027
0.27 0.07%
unlock
2028
0.22 20.35%
unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today